Leap Therapeutics, Inc. (LPTX)
Stock Price:
$1.96 USD
-0.05 (-2.49%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
109.86M |
| Revenue (ttm) |
375,000 |
| Net Income (ttm) |
-31.53M |
| Shares Out |
56.05M |
| EPS (ttm) |
-1.62 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$1.96 |
| Previous Close |
$2.01 |
| Change ($) |
-0.05 |
| Change (%) |
-2.49% |
| Day's Open |
2.00 |
| Day's Range |
1.93 - 2.03 |
| Day's Volume |
479,284 |
| 52-Week Range |
0.57 - 3.18 |
More Stats
| Market Cap |
109.86M |
| Enterprise Value |
83.77M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
56.05M |
| Float |
21.26M |
| EPS (basic) |
-1.57 |
| EPS (diluted) |
-1.62 |
| FCF / Share |
-0.76 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.19M |
| Short Ratio |
3.13 |
| Short % of Float |
8.32% |
| Beta |
1.95 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
292.95 |
| PB Ratio |
6.27 |
| Revenue |
375,000 |
| Operating Income |
-31.04M |
| Net Income |
-31.53M |
| Free Cash Flow |
-23.95M |
| Net Cash |
26.09M |
| Net Cash / Share |
0.47 |
| Gross Margin |
n/a |
| Operating Margin |
-8,276.53% |
| Profit Margin |
-11,093.90% |
| FCF Margin |
-6,385.33% |
| ROA |
-70.44% |
| ROE |
-180.02% |
| ROIC |
679.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
3 |
| Overweight |
2 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$5.50*
(180.61% upside)
Low
2.50
Current: 1.96
High
8.00
Target: 5.50
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -33.45 | -30.75 | -32.35 | -27.30 | -11.92 |
| Net Income | -32.90 | -23.14 | -29.73 | -25.63 | -12.05 |
| Shares Outstanding | 22.58 | 14.14 | 9.16 | 9.39 | - |
| Earnings Per Share | -1.47 | -2.11 | -3.31 | - | - |
| Operating Cash Flow | -26.90 | -26.03 | -22.14 | -25.34 | -8.10 |
| Capital Expenditures | -0.09 | - | -0.06 | -0.14 | - |
| Free Cash Flow | -26.99 | -26.03 | -22.20 | -25.48 | -8.10 |
| Cash & Equivalents | 4.99 | 17.66 | 25.74 | 0.79 | 0.41 |
| Total Debt | 0.55 | - | - | 30.27 | 3.14 |
| Net Cash / Debt | 4.44 | 17.66 | 25.74 | -29.48 | -2.74 |
| Assets | 7.45 | 19.07 | 29.06 | 6.46 | 1.26 |
| Liabilities | 9.20 | 9.90 | 17.95 | 36.16 | 71.55 |
| Book Value | -1.75 | 9.18 | 11.12 | -100 | -70.29 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Leap Therapeutics, Inc. |
| Country |
United States |
| Employees |
24 |
| CEO |
Doug E. Onsi |
Stock Information
| Ticker Symbol |
LPTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: LPTX |
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company's clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.